This medication is a dual GIP and GLP-1 receptor agonist providing comprehensive metabolic regulation. It enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite, resulting in effective glycemic control and clinically meaningful weight loss.
Recommended for:
Clinical evidence:
Tirzepatide has been evaluated in the global SURPASS clinical trial program, consisting of multicenter randomized studies. These trials demonstrated superior reductions in HbA1c and body weight compared with insulin glargine and GLP-1 receptor agonists. The medication is approved by the FDA and EMA, confirming its efficacy and safety for long-term use.
The product is used to improve blood glucose regulation and overall metabolic health with consistent weekly administration.
Administered subcutaneously once weekly. One vial contains four doses, providing a complete one-month treatment course. Dose selection and titration should be determined by a healthcare professional. Not intended for intravenous or intramuscular use.
Contraindications:
Side effects:
